Our team came back from AD/PD 2026 energized, with one clear takeaway: interest in Amyl Therapeutics is growing rapidly.
Our two presentations, given by Damien Toulorge, CSO, and Aditya Iyer, Senior Project Manager, boosted our international visibility and led to many high-quality discussions with experts, potential partners, and key players across the field.
💡 The congress confirmed our vision aligns with real-world challenges and highlighted the innovation and relevance of our technology.
The presentations and poster displayed during the conference are available on our page Science.
